Bulk Inquiry
PCI 32765
- Ibrutinib
Axon 1858
CAS:
936563-96-1
Purity:
99%
- Soluble in DMSO
- MF: C25H24N6O2
- MW: 440.5
Description
Orally bioavailable and highly selective inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity; inhibiting BTK activity, B-cell-mediated signaling and the growth of malignant B cells that overexpress BTK; an experimental drug candidate for chronic lymphocytic leukemia (CLL), mantle cell lymphoma, diffuse large B-cell lymphoma, and multiple myeloma etcBTK, a member of the BTK/Tec family of non-recetor cytoplasmic tyrosine kinases, is required for B cell receptor (BCR) signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies
More Information
| Parent CAS No. | 936563-96-1 |
|---|---|
| Chemical Name | (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one |
| MFCD | N.A. |
| Short Description | BTK inhibitor |
References
- Z Pan et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007, 2(1), 58–61.
- LA Honigberg et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Nat. Acad. Sci. USA 2010, 107(29), 13075–80.
- ES Winer et al. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin. Investig. Drugs. 2012, 21(3), 355-61.
Other Categories
Get a Quote for
Loading...
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.